Business

Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties

Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties

articleCansino Biologics, Inc. Class AFebruary 7, 20254/news/announcement-on-voluntary-disclosure-of-formal-inclusion-of-the-drug-registration-application-for-the-diphtheria-tetanus-and-acellular-pertussis-component-combined-vaccine-adsorbed-for-infants-and-young-children-in-priority-review-varieties
Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties

About this update from Cansino Biologics, Inc. Class A

Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review VarietiesThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A